Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Korea ETF (EWY) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares MSCI South Korea ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Korea ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $166.06, while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EWYHRTX
Sector
Broad Market / FactorHealth
52-Week High
$219.20$2.02
52-Week Low
$70.65$0.39
Market Cap
$84.50M
Enterprise Value
$182.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Korea ETF

EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.

The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.

Heron Therapeutics Inc

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX